Press releases

Funding to Four Community Health Centers Advances Medication Management Programs for Vulnerable Patients Managing Chronic Disease FRANKLIN LAKES, N.J., Aug. 8, 2022 /PRNewswire/ -- BD (Becton,...

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis Revenue from continuing operations driven by base revenue growth of 6.0% as...

Acquisition adds to company's recent growth in high-technology pharmacy solutions and further accelerates the company's commitment to Smart, Connected Care – offering a customizable platform to...

Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J., July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on September 30, 2022 to holders of record on...

Top Score on Disability Equality Index Demonstrates Progress in Removing Barriers and Creating Employment Opportunities for People with Disabilities FRANKLIN LAKES, N.J., July 20, 2022...

FRANKLIN LAKES, N.J. (July 19, 2022) — Recent research published in the Journal of the American College of Clinical Pharmacy shows that investments made in clinical pharmacist-led patient care...

- BD enters growing pharmacy automation market segment by offering a comprehensive set of technologies across the care continuum - Addition of Parata aligns with two key tenets of BD's innovation...

BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its third quarter of fiscal year 2022 on Thursday, August 4, 2022. A news release will be...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Rishi Grover has been named executive vice president (EVP) and chief integrated...

Company makes notable progress toward 2030+ ESG commitments, addressing energy, water and waste reduction, environmental impact of product portfolio and supplier diversification FRANKLIN LAKES, N.J.,

BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive FRANKLIN LAKES, N.J., June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today unveiled findings from a survey conducted by The Harris...

BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on the BD™ Intraosseous Needle Set Kits, BD™ Intraosseous Manual Driver Kits and...

BD is among the first companies to enter innovative partnership with Mayo Clinic Platform for access to world's largest collection of clinical data FRANKLIN LAKES, N.J., June 13, 2022 /PRNewswire/...

CerTest Biotec Uses the BD MAX™ Molecular Diagnostic System Open System Reagent Suite to Develop RT-PCR Detection Kit ZARAGOZA, Spain and FRANKLIN LAKES, N.J., June 8, 2022 /PRNewswire/ --...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as executive vice president (EVP) and president of the...

Expands BD Transformative Solutions to Provide New Pharmacy Automation Technologies for Hospitals, Retail Pharmacy, Long-Term Care and Home Settings Advances BD 2025 Strategy to Accelerate...

BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology First to Combine Spectral Flow Cytometry with Sort-Capable Imaging FRANKLIN LAKES, N.J., June 3, 2022 /PRNewswire/ -- BD...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman Sachs 43rd Annual Global Healthcare Conference on...

Second Test for the BD COR™ MX to be CE Marked to IVD Directive FRANKLIN LAKES, N.J., May 26, 2022 / B3C newswire / -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

FRANKLIN LAKES, N.J. (May 18, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Mitsubishi Gas Chemical Company, Inc. (MGC), a R&D-oriented...

FRANKLIN LAKES, N.J. (May 13, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named a “Noteworthy...

BD First Participant in Intermountain’s ‘Impact Hire’ Program for Strategic Suppliers​ SALT LAKE CITY (May 12, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global...

510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J., May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)...

Expanded Collaboration Agreement to Make Less Invasive Blood Sample Collection More Convenient and Patient Centered AUSTIN, Texas and FRANKLIN LAKES, N.J., May 11, 2022 /PRNewswire/ -- Babson...

Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis Revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline...

Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology FRANKLIN LAKES, N.J., May 2, 2022 /PRNewswire/ -- BD (Becton,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday,...

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on June 30, 2022 to holders of record on June 9, 2022....

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as one of the top employers in the U.S. for...

Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and...

Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments...

BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022. A news release will be...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC), which...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley")...

FRANKLIN LAKES, N.J. (Mar 30, 2022) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, recently released the BD Rhapsody™ TCR/BCR Multiomic Assay,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted...

Record date for spin-off is March 22, 2022 "When Issued" trading of embecta common stock is expected to begin on March 21, 2022, under the ticker "EMBCV" BD expects the spin-off of embecta to be...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022.

FRANKLIN LAKES, N.J. and INDIANAPOLIS (Feb. 25, 2022) – USA Track & Field and BD, a leading global medical technology company, today announced the extension of BD’s sponsorship through 2022....

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will virtually present at the Cowen 42nd Annual Health Care Conference via...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022. Neal,...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that embecta, the diabetes care business that is expected to spin off from BD on April 1,...

FRANKLIN LAKES, N.J., Feb. 22, 2022 -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it ranked No. 1 in the Health Care Equipment &...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business,...